AtriCure (NASDAQ:ATRC) Hits New 12-Month High on Analyst Upgrade

AtriCure, Inc. (NASDAQ:ATRC) shares hit a new 52-week high during mid-day trading on Monday after BTIG Research raised their price target on the stock from $45.00 to $55.00. BTIG Research currently has a buy rating on the stock. AtriCure traded as high as $49.58 and last traded at $49.30, with a volume of 15650 shares changing hands. The stock had previously closed at $48.98.

Several other equities research analysts have also issued reports on the stock. Citigroup reiterated a “market outperform” rating on shares of AtriCure in a research note on Tuesday, July 21st. UBS Group lowered their target price on AtriCure from $55.00 to $50.00 and set a “buy” rating on the stock in a research report on Tuesday, July 28th. Weiss Ratings upgraded AtriCure from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday. Zacks Research upgraded AtriCure from a “hold” rating to a “strong-buy” rating in a research note on Friday, July 24th. Finally, Raymond James Financial set a $52.00 price objective on AtriCure in a research note on Tuesday, July 21st. Two equities research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $48.62.

Insider Activity

In other AtriCure news, Director Karen Prange sold 3,564 shares of the business’s stock in a transaction on Wednesday, August 5th. The shares were sold at an average price of $38.80, for a total transaction of $138,283.20. Following the sale, the director owned 22,809 shares of the company’s stock, valued at approximately $884,989.20. The trade was a 13.51% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Vinayak Doraiswamy sold 6,000 shares of the business’s stock in a transaction dated Tuesday, July 28th. The stock was sold at an average price of $38.88, for a total value of $233,280.00. Following the sale, the insider owned 86,511 shares in the company, valued at approximately $3,363,547.68. This trade represents a 6.49% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 44,246 shares of company stock worth $1,691,895. 4.00% of the stock is currently owned by insiders.

Institutional Trading of AtriCure

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. California State Teachers Retirement System grew its position in shares of AtriCure by 2,627.3% in the 2nd quarter. California State Teachers Retirement System now owns 1,634,927 shares of the medical device company’s stock valued at $45,745,000 after buying an additional 1,574,980 shares during the last quarter. Three Seasons Wealth LLC bought a new stake in shares of AtriCure in the 2nd quarter valued at $200,000. Grandeur Peak Global Advisors LLC raised its stake in AtriCure by 53.8% during the second quarter. Grandeur Peak Global Advisors LLC now owns 587,399 shares of the medical device company’s stock worth $16,435,000 after buying an additional 205,497 shares during the last quarter. Headlands Technologies LLC bought a new stake in AtriCure during the second quarter valued at $282,000. Finally, Susquehanna Fundamental Investments LLC bought a new position in shares of AtriCure in the 2nd quarter worth about $1,413,000. 99.11% of the stock is currently owned by institutional investors and hedge funds.

AtriCure Price Performance

The business has a 50 day moving average price of $35.83 and a 200-day moving average price of $31.81. The company has a market capitalization of $2.51 billion, a price-to-earnings ratio of 235.06 and a beta of 1.20. The company has a debt-to-equity ratio of 0.14, a quick ratio of 3.19 and a current ratio of 4.22.

AtriCure (NASDAQ:ATRC) last announced its quarterly earnings data on Thursday, July 23rd. The medical device company reported $0.18 EPS for the quarter. AtriCure had a net margin of 1.85% and a return on equity of 2.34%. The company had revenue of $153.60 million during the quarter, compared to the consensus estimate of $151.80 million. During the same quarter last year, the firm posted ($0.13) EPS. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. Research analysts predict that AtriCure, Inc. will post 0.2 EPS for the current fiscal year.

AtriCure Company Profile

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.